{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T22:23:42Z","timestamp":1776810222952,"version":"3.51.2"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.cct.2019.105859","type":"journal-article","created":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T12:47:18Z","timestamp":1571921238000},"page":"105859","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Rationale and design of a randomized pragmatic trial of patient-centered models of hepatitis C treatment for people who inject drugs: The HERO study"],"prefix":"10.1016","volume":"87","author":[{"given":"Alain H.","family":"Litwin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Jost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moonseong","family":"Heo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Karasz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Feinberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula J.","family":"Lum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shruti H.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn E.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith I.","family":"Tsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Pericot-Valverde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Page","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.cct.2019.105859_bb0005","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1093\/cid\/ciw111","article-title":"Rising mortality associated with hepatitis C virus in the United States, 2003\u20132013","volume":"62","author":"Ly","year":"2016","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.cct.2019.105859_bb0010","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2105\/AJPH.2017.304132","article-title":"Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014","volume":"108","author":"Zibbell","year":"2018","journal-title":"Am. J. Public Health"},{"issue":"9791","key":"10.1016\/j.cct.2019.105859_bb0015","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(11)61097-0","article-title":"Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews","volume":"78","author":"Nelson","year":"2011","journal-title":"Lancet."},{"issue":"1","key":"10.1016\/j.cct.2019.105859_bb0020","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/liv.13949","article-title":"Hepatitis C elimination among people who inject drugs: challenges and recommendations for action withing a health systems framework","volume":"39","author":"Day","year":"2019","journal-title":"Liver Int."},{"key":"10.1016\/j.cct.2019.105859_bb0025","series-title":"HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C","author":"American Association for the Study of Liver Diseases and the Infectious Diseases Society of America","year":"2019"},{"issue":"Suppl. 2","key":"10.1016\/j.cct.2019.105859_bb0030","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1093\/cid\/cit302","article-title":"Recommendations for the management of hepatitis C virus infection among people who inject drugs","volume":"57","author":"Robaeys","year":"2013","journal-title":"Clin. Infect. Dis."},{"issue":"10","key":"10.1016\/j.cct.2019.105859_bb0035","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.drugpo.2015.05.002","article-title":"Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic hepatitis C care continuum","volume":"26","author":"Meyer","year":"2015","journal-title":"Int. J. Drug Policy"},{"issue":"Suppl. 2","key":"10.1016\/j.cct.2019.105859_bb0040","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1093\/cid\/cit271","article-title":"Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all","volume":"57","author":"Bruggmann","year":"2013","journal-title":"Clin. Infect. Dis."},{"issue":"5","key":"10.1016\/j.cct.2019.105859_bb0045","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/hep.26431","article-title":"Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals","volume":"58","author":"Martin","year":"2013","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cct.2019.105859_bb0050","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/jvh.12129","article-title":"Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999\u20132011","volume":"21","author":"Iversen","year":"2014","journal-title":"J. Viral Hepat."},{"issue":"18","key":"10.1016\/j.cct.2019.105859_bb0055","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1097\/QAD.0b013e32801086da","article-title":"Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic","volume":"20","author":"Mehta","year":"2006","journal-title":"AIDS."},{"issue":"3","key":"10.1016\/j.cct.2019.105859_bb0060","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s10900-007-9083-3","article-title":"Limited uptake of hepatitis C treatment among injection drug users","volume":"33","author":"Mehta","year":"2008","journal-title":"J. Community Health"},{"issue":"1\u20132","key":"10.1016\/j.cct.2019.105859_bb0065","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.drugalcdep.2007.09.008","article-title":"Barriers associated with the treatment of hepatitis C virus infection among illicit drug users","volume":"93","author":"Grebely","year":"2008","journal-title":"Drug Alcohol Depend."},{"issue":"12","key":"10.1016\/j.cct.2019.105859_bb0070","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1089\/apc.2009.0153","article-title":"Factors that influence an HIV coinfected patient\u2019s decision to start hepatitis C treatment","volume":"23","author":"Osilla","year":"2009","journal-title":"AIDS Patient Care STDs"},{"issue":"17","key":"10.1016\/j.cct.2019.105859_bb0075","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/j.1465-3362.2012.00468.x","article-title":"Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs","volume":"31","author":"Treloar","year":"2012","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.cct.2019.105859_bb0080","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1097\/01.aids.0000192088.72055.90","article-title":"A framework for understanding factors that affect access and utilization of treatment for hepatitis C virus infection among HCV-mono-infected and HIV\/HCV-co-infected injection drug users","volume":"19","author":"Mehta","year":"2005","journal-title":"AIDS"},{"issue":"Suppl. 1","key":"10.1016\/j.cct.2019.105859_bb0085","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1093\/infdis\/jis928","article-title":"Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV\/HIV coinfection: action required at the system, provider, and patient levels","volume":"207","author":"Grebely","year":"2013","journal-title":"J. Infect. Dis."},{"issue":"12","key":"10.1016\/j.cct.2019.105859_bb0090","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1089\/apc.2010.0142","article-title":"Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration","volume":"24","author":"Swan","year":"2010","journal-title":"AIDS Patient Care STDs"},{"issue":"1","key":"10.1016\/j.cct.2019.105859_bb0095","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.japh.2017.10.013","article-title":"American academy of HIV medicine pharmacists committee. Improving patient access to hepatitis C virus treatment","volume":"58","author":"McLaughlin","year":"2018","journal-title":"J. Am. Pharm. Assoc."},{"issue":"Suppl. 2","key":"10.1016\/j.cct.2019.105859_bb0100","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1093\/cid\/cit305","article-title":"Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study","volume":"57","author":"Alavi","year":"2013","journal-title":"Clin. Infect. Dis."},{"issue":"11","key":"10.1016\/j.cct.2019.105859_bb0105","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1111\/j.1572-0241.2008.02065.x","article-title":"Efficacy and safety of peginterferon alfa-2a\/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration","volume":"103","author":"Bonkovsky","year":"2008","journal-title":"Am. J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.cct.2019.105859_bb0110","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.dld.2008.08.009","article-title":"Peginterferon plus ribavirin for chronic hepatitis C in opioid addicts on methadone\/buprenorphine maintenance therapy","volume":"41","author":"Belfiori","year":"2009","journal-title":"Dig. Liver Dis."},{"issue":"3","key":"10.1016\/j.cct.2019.105859_bb0115","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3109\/00952990.2011.643975","article-title":"Developing a modified directly observed therapy intervention for hepatitis C treatment in a methadone maintenance program: implications for program replication","volume":"38","author":"Bruce","year":"2012","journal-title":"Am. J. Drug Alcohol Abuse."},{"issue":"1","key":"10.1016\/j.cct.2019.105859_bb0120","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jsat.2008.09.009","article-title":"Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program","volume":"37","author":"Litwin","year":"2009","journal-title":"J. Subst. Abus. Treat."},{"issue":"1","key":"10.1016\/j.cct.2019.105859_bb0125","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2893.2010.01411.x","article-title":"Integrated internist - addiction medicine - hepatology model for hepatitis C management for individuals on methadone maintenance","volume":"19","author":"Martinez","year":"2012","journal-title":"J. Viral Hepat."},{"issue":"6","key":"10.1016\/j.cct.2019.105859_bb0130","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/cid\/cis1007","article-title":"Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis","volume":"56","author":"Dimova","year":"2013","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.cct.2019.105859_bb0135","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1365-2036.2008.03872.x","article-title":"Clinical trial: a primary-care-based model for the delivery of anti-viral treatment to injecting drug users infected with hepatitis C","volume":"29","author":"Jack","year":"2009","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.cct.2019.105859_bb0140","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jcv.2014.09.004","article-title":"Uptake of hepatitis C specialist services and treatment following diagnosis by dried blood spot in Scotland","volume":"61","author":"McAllister","year":"2014","journal-title":"J. Clin. Virol."},{"issue":"5","key":"10.1016\/j.cct.2019.105859_bb0145","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1007\/s10900-014-9932-9","article-title":"Strategies for hepatitis C testing and linkage to care for vulnerable populations: point-of-care and standard HCV testing in a mobile medical clinic","volume":"39","author":"Morano","year":"2014","journal-title":"J. Community Health"},{"issue":"4","key":"10.1016\/j.cct.2019.105859_bb0150","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1155\/2013\/515636","article-title":"Treatment of chronic hepatitis C infection among current and former injection drug users within a multidisciplinary treatment model at community health centre","volume":"27","author":"Newman","year":"2013","journal-title":"Can. J. Gastroeneterol."},{"issue":"9","key":"10.1016\/j.cct.2019.105859_bb0155","article-title":"Patients receiving opioid maintenance treatment in primary care: successful chronic hepatitis C care in a real world setting","volume":"13","author":"Seidenberg","year":"2013","journal-title":"BMC Infect. Dis."},{"issue":"5","key":"10.1016\/j.cct.2019.105859_bb0160","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.drugpo.2007.01.009","article-title":"Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection","volume":"18","author":"Grebely","year":"2007","journal-title":"Int. J. Drug Policy"},{"issue":"5","key":"10.1016\/j.cct.2019.105859_bb0165","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.drugpo.2007.01.010","article-title":"Integrating HCV services for drug users: a model to improve engagement and outcomes","volume":"18","author":"Sylvestre","year":"2007","journal-title":"Int. J. Drug Policy"},{"issue":"4","key":"10.1016\/j.cct.2019.105859_bb0170","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jsat.2012.08.007","article-title":"Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program","volume":"43","author":"Stein","year":"2012","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.cct.2019.105859_bb0175","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1186\/1471-2334-11-315","article-title":"Rationale and design of a randomized controlled trial of directly observed hepatitis C treatment delivered in methadone clinics","volume":"11","author":"Litwin","year":"2011","journal-title":"BMC Infect. Dis."},{"issue":"8","key":"10.1016\/j.cct.2019.105859_bb0180","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.gastrohep.2014.03.004","article-title":"Directly observed therapy for chronic hepatitis C: a randomized clinical trial in the prison setting","volume":"37","author":"Saiz de la Hoya","year":"2014","journal-title":"Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.cct.2019.105859_bb0185","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0197-2456(88)90048-7","article-title":"Properties of the urn randomization in clinical trials","volume":"9","author":"Wei","year":"1988","journal-title":"Control. Clin. Trials"},{"issue":"2","key":"10.1016\/j.cct.2019.105859_bb0190","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.drugalcdep.2004.04.018","article-title":"The Addiction Severity Index medical and psychiatric composite scores measure similar domains as the SF-36 in substance-dependent veterans: concurrent and discriminant validity","volume":"76","author":"Calsyn","year":"2004","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"10.1016\/j.cct.2019.105859_bb0195","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0149-7189(94)90035-3","article-title":"Validity of self-reported drug use among injection drug users and crack cocaine users recruited through street outreach","volume":"17","author":"Weatherby","year":"1994","journal-title":"Eval. Program Plan."},{"issue":"6","key":"10.1016\/j.cct.2019.105859_bb0200","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1360-0443.1993.tb02093.x","article-title":"Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption\u2013II","volume":"88","author":"Saunders","year":"1993","journal-title":"Addiction"},{"issue":"9","key":"10.1016\/j.cct.2019.105859_bb0205","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J. Gen. Intern. Med."},{"issue":"10","key":"10.1016\/j.cct.2019.105859_bb0210","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch. Intern. Med."},{"issue":"5","key":"10.1016\/j.cct.2019.105859_bb0215","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","article-title":"Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets","volume":"15","author":"van Hout","year":"2012","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.cct.2019.105859_bb0220","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jadohealth.2006.08.001","article-title":"Stigma scale revised: reliability and validity of a brief measure of stigma for HIV+ youth","volume":"40","author":"Wright","year":"2007","journal-title":"J. Adolesc. Health"},{"issue":"2","key":"10.1016\/j.cct.2019.105859_bb0225","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1037\/0022-3514.84.2.365","article-title":"What good are positive emotions in crises? A prospective study of resilience and emotions following the terrorist attacks on the United States on September 11th, 2001","volume":"84","author":"Fredrickson","year":"2003","journal-title":"J. Pers. Soc. Psychol."},{"issue":"6","key":"10.1016\/j.cct.2019.105859_bb0230","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/0277-9536(91)90150-B","article-title":"The MOS social support survey","volume":"32","author":"Sherbourne","year":"1991","journal-title":"Soc. Sci. Med."},{"issue":"5","key":"10.1016\/j.cct.2019.105859_bb0235","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/cid\/ciw806","article-title":"From care to cure: demonstrating a model of clinical patient navigation for hepatitis C care and treatment in high-need patients","volume":"64","author":"Ford","year":"2017","journal-title":"Clin. Infect. Dis."},{"issue":"74","key":"10.1016\/j.cct.2019.105859_bb0240","article-title":"Community-based HCV screening: knowledge and attitudes in a high risk urban population","volume":"14","author":"Norton","year":"2014","journal-title":"BMC Infect. Dis."},{"issue":"6","key":"10.1016\/j.cct.2019.105859_bb0245","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1037\/0022-3514.51.6.1173","article-title":"The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations","volume":"51","author":"Baron","year":"1986","journal-title":"J. Pers. Soc. Psychol."},{"issue":"1","key":"10.1016\/j.cct.2019.105859_bb0250","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/cid\/ciw676","article-title":"Late relapse versus hepatitis C virus reinfection in patients with sustained virologic response after Sofosbuvir-based therapies","volume":"64","author":"Sarrazin","year":"2016","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.cct.2019.105859_bb0255","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12160-007-9008-5","article-title":"What types of evidence are most needed to advance behavioral medicine?","volume":"35","author":"Glasgow","year":"2008","journal-title":"Ann. Behav. Med."},{"issue":"3","key":"10.1016\/j.cct.2019.105859_bb0260","first-page":"289","article-title":"Qualitative analysis: how to begin making sense","volume":"14","author":"Miller","year":"1994","journal-title":"Fam. Pract. Res. J."},{"issue":"4","key":"10.1016\/j.cct.2019.105859_bb0265","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1370\/afm.31","article-title":"Women\u2019s experiences of abnormal cervical cytology: illness representations, care processes, and outcomes","volume":"1","author":"Karasz","year":"2003","journal-title":"Ann. Fam. Med."},{"issue":"4","key":"10.1016\/j.cct.2019.105859_bb0270","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s10461-014-0837-5","article-title":"Barriers and facilitators to the implementation of SPNS interventions designed to engage and retain HIV positive women of color in medical care","volume":"19","author":"Garcia","year":"2015","journal-title":"AIDS Behav."},{"issue":"6","key":"10.1016\/j.cct.2019.105859_bb0275","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1370\/afm.124","article-title":"Health care seeking among urban minority adolescent girls: the crisis at sexual debut","volume":"2","author":"McKee","year":"2004","journal-title":"Ann. Fam. Med."},{"issue":"7","key":"10.1016\/j.cct.2019.105859_bb0280","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.socscimed.2004.08.011","article-title":"Cultural differences in conceptual models of depression","volume":"60","author":"Karasz","year":"2005","journal-title":"Soc. Sci. Med."},{"key":"10.1016\/j.cct.2019.105859_bb0285","series-title":"HCV Reinfection and Spontaneous Clearance after Spontaneous Clearance of Primary HCV Infection: The InC3 Study","author":"Sacks-Davis","year":"2013"},{"issue":"9","key":"10.1016\/j.cct.2019.105859_bb0290","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1093\/infdis\/jis213","article-title":"The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design","volume":"205","author":"Vickerman","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.cct.2019.105859_bb0295","series-title":"Effects of SVR on the Risk of Liver Transplant, Hepatocellular Carcinoma, Death and Reinfection: Meta-analysis of 129 Studies in 34,563 Patients with Hepatitis C Infection","author":"Hill","year":"2014"},{"issue":"1","key":"10.1016\/j.cct.2019.105859_bb0300","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1053\/j.gastro.2009.09.017","article-title":"Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection","volume":"138","author":"Osburn","year":"2010","journal-title":"Gastroenterology"},{"issue":"9316","key":"10.1016\/j.cct.2019.105859_bb0305","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/S0140-6736(02)08435-0","article-title":"Protection against persistence of hepatitis C","volume":"359","author":"Mehta","year":"2002","journal-title":"Lancet"}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714419305749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714419305749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:47:47Z","timestamp":1761554867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714419305749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":61,"alternative-id":["S1551714419305749"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2019.105859","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale and design of a randomized pragmatic trial of patient-centered models of hepatitis C treatment for people who inject drugs: The HERO study","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2019.105859","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"105859"}}